Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules.
Strom
T B
TB
Department of Medicine, Beth Israel Hospital, Boston, MA.
Kelley
V R
VR
Woodworth
T G
TG
Murphy
J R
JR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D000922:Immunotoxins / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D015375:Receptors, Interleukin-2